Get the Stockscreener App
1.52
1.33%
0.02
After Hours:
1.53
0.01
+0.66%
Cibus Inc stock is traded at $1.52, with a volume of 66,793.
It is up +1.33% in the last 24 hours and down -9.52% over the past month.
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
See More
Previous Close:
$1.50
Open:
$1.51
24h Volume:
66,793
Relative Volume:
0.29
Market Cap:
$116.17M
Revenue:
$4.29M
Net Income/Loss:
$-104.03M
P/E Ratio:
-0.7722
EPS:
-1.9685
Net Cash Flow:
$-50.65M
1W Performance:
-5.59%
1M Performance:
-9.52%
6M Performance:
-47.04%
1Y Performance:
+16.92%
1-Day Range:
$1.48
$1.5394
1-Week Range:
$1.48
$1.675
52-Week Range:
$1.09
$4.1907
Cibus Inc Stock (CBUS) Company Profile
Name
Cibus Inc
Sector
Industry
Phone
(858) 450-0008
Address
6455 NANCY RIDGE DRIVE, SAN DIEGO
Compare CBUS vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CBUS
Cibus Inc
|
1.52 | 116.17M | 4.29M | -104.03M | -50.65M | -1.9685 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cibus Inc Stock (CBUS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-29-24 | Initiated | Alliance Global Partners | Buy |
| Jul-19-24 | Resumed | Canaccord Genuity | Buy |
| Oct-09-23 | Initiated | H.C. Wainwright | Buy |
| Jul-19-23 | Resumed | Canaccord Genuity | Buy |
Cibus Inc Stock (CBUS) Latest News
CBUS PE Ratio & Valuation, Is CBUS Overvalued - Intellectia AI
Cibus, Inc.(NasdaqCM: CBUS) added to S&P Global BMI Index - marketscreener.com
Wall Street Zen Downgrades Cibus (NASDAQ:CBUS) to Sell - MarketBeat
CBUS Q2 2026 Earnings: Wider-Than-Expected Loss as Gene-Editing Platform Awaits Commercial ScaleTax Rate Impact - dars.gov.et
Cibus (NASDAQ:CBUS) Trading 1.3% HigherWhat's Next? - MarketBeat
Cibus (CBUS) Reports Q2 Loss, Misses Revenue Estimates - Eastern Progress
Calibre One Assists Cibus with CEO Search - Hunt Scanlon Media
Cibus (CBUS) Outlook: Closes with Limited Movement at $1.70 in the Latest Session; Chart View - vinanet.vn
EU rules favor Cibus non-transgenic crop improvements - scanx.trade
Cibus (CBUS) Q2 2026 Earnings Call Transcript - AOL.com
Cibus (CBUS) Session: Finishes 1.18% Down at $1.68 in Latest Trading; Immediate View: the $1.60 to $1.76 Range Remains in Focus in the Current UpdateFibonacci Retracement - vinanet.vn
Cibus Inc (CBUS) Stock News Today - TradingKey
HC Wainwright Estimates Cibus' Q3 Earnings (NASDAQ:CBUS) - MarketBeat
Cibus Inc: Interoc Expands Rice Trade to 5 Traits, 36% Revenue Growth – Quarterly Update Report - Yahoo Finance
HC Wainwright Issues Pessimistic Forecast for Cibus Earnings - MarketBeat
Cibus Is Trying To Turn Gene-Edited Traits Into Royalties - Finimize
Cibus Inc. (CBUS) Drops 6.84% to $1.77, Testing Critical Support at $1.68Breadth Thrust - vinanet.vn
Teleconferência de Resultados do 2T26 da Cibus (CBUS): Lançamento do Arroz Passa para 2028 com Queda de Custos - TradingKey
CBUS Q2 2026 Earnings: Wider Loss and Nil Revenue Reinforce Pre-Commercial ProfileProfit Cycle Analysis - vinanet.vn
Cibus Inc. (CBUS) Edges Higher at $1.90 as Shares Test Technical ResistanceComposite Profile - vinanet.vn
Cibus, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Conferencia de resultados del T2 de 2026 de Cibus (CBUS): El lanzamiento del arroz se traslada a 2028 a medida que disminuyen los costos - TradingKey
Cibus (CBUS) Q2 2026 Earnings Call: Rice Launch Moves to 2028 as Costs Decline - TradingKey
Cibus Inc (CBUS) (Q2 2026) Earnings Call Highlights: Strategic P - GuruFocus
Cibus Q2 2026 Earnings Call Transcript - MarketBeat
CBUS Looks 4.7% Undervalued on GF Value™ - GuruFocus
Cibus (NASDAQ:CBUS) Releases Earnings Results - MarketBeat
Cibus Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Cibus Q2 2026 revenue miss sparks 16% after-hours drop - Investing.com
Cibus Q2 Results: Revenue rises 11% YoY, cash usage drops 31% - scanx.trade
Transcript: Cibus Q2 2026 Earnings Conference Call - Benzinga
Cibus Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cibus: Q2 Earnings Snapshot - marketscreener.com
Cibus (CBUS) cuts costs but warns on going concern amid Q2 2026 loss - Stock Titan
Q2 2026 Cibus Inc Earnings Call Transcript - GuruFocus
Cibus (CBUS) narrows Q2 2026 loss as cash burn falls and regulatory tailwinds build - Stock Titan
Cibus Reports Second Quarter Financial Results and Provides Business Update - The Manila Times
Earnings To Watch: Cibus Inc (CBUS) Q2 2026 -- GF Value Sees 14% Downside - Yahoo Finance
CBUS Q1 2026 Earnings: Modest EPS Beat Signals Cost DisciplineSubscription Growth Report - dars.gov.et
Cibus Inc. (CBUS) Jumps 6.6% to $1.93, Holding Above Key SupportSafe Entry Stocks - dars.gov.et
Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close and Host Conference Call - 富途牛牛
CBUS Q1 2026 Earnings: Narrower-Than-Expected Loss of -$0.33, Shares Edge Down 3.21%Profit Guidance Range - careplusvn.com
Cibus Inc (CBUS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CBUS Q2'26 Earnings: revenue estimate is 1.70M USD - TradingView
Cibus (CBUS) Projected to Post Quarterly Earnings on Thursday - MarketBeat
CBUS Dips 3.11% to $1.87: Cibus Inc. Tests Key Support at $1.78PCR Spike - dars.gov.et
Cibus expands global footprint with AgVayā partnership targeting India’s rice market - AgroSpectrum India
Cibus Inc. (CBUS) Advances 1.59% to $1.92: Biotech Stock Holds Key Support Amid ConsolidationAdaptive Moving Average - dars.gov.et
Cibus Inc. (CBUS) Steadies at $1.93: Consolidation Between $1.83 Support and $2.03 ResistanceRetail Driven Moves - dars.gov.et
Cibus to Report Second Quarter 2026 Financial Results on August 13, 2026 After the Market Close ... - Caledonian Record
Cibus to Report Second Quarter 2026 Financial Results on - GlobeNewswire
Cibus Inc Stock (CBUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):